{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T07:40:23Z","timestamp":1725867623435},"publisher-location":"Singapore","reference-count":74,"publisher":"Springer Singapore","isbn-type":[{"type":"print","value":"9789811020407"},{"type":"electronic","value":"9789811020414"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-981-10-2041-4_9","type":"book-chapter","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T01:51:04Z","timestamp":1476237064000},"page":"105-121","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Trials and a View Toward the Future of ADPKD"],"prefix":"10.1007","author":[{"given":"Hyunsuk","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hwan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,13]]},"reference":[{"issue":"2","key":"9_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000346812","volume":"37","author":"G Aguiari","year":"2013","unstructured":"Aguiari G, Catizone L, Del Senno L (2013) Multidrug therapy for polycystic kidney disease: a review and perspective. Am J Nephrol 37(2):175\u2013182. doi: 10.1159\/000346812","journal-title":"Am J Nephrol"},{"issue":"4","key":"9_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2215\/CJN.04180609","volume":"5","author":"I Barash","year":"2010","unstructured":"Barash I, Ponda MP, Goldfarb DS, Skolnik EY (2010) A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol CJASN 5(4):693\u2013697. doi: 10.2215\/CJN.04180609","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"8","key":"9_CR3","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1681\/ASN.2009020162","volume":"20","author":"M Barua","year":"2009","unstructured":"Barua M, Cil O, Paterson AD, Wang K, He N, Dicks E, Parfrey P, Pei Y (2009) Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol JASN 20(8):1833\u20131838. doi: 10.1681\/ASN.2009020162","journal-title":"J Am Soc Nephrol JASN"},{"issue":"3","key":"9_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3904\/kjim.2009.24.3.165","volume":"24","author":"WM Bennett","year":"2009","unstructured":"Bennett WM (2009) Autosomal dominant polycystic kidney disease: 2009 update for internists. Korean J Intern Med 24(3):165\u2013168. doi: 10.3904\/kjim.2009.24.3.165","journal-title":"Korean J Intern Med"},{"issue":"23","key":"9_CR5","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMra1403672","volume":"372","author":"T Berl","year":"2015","unstructured":"Berl T (2015) Vasopressin antagonists. N Engl J Med 372(23):2207\u20132216. doi: 10.1056\/NEJMra1403672","journal-title":"N Engl J Med"},{"key":"9_CR6","doi-asserted-by":"publisher","first-page":"Cd010294","DOI":"10.1002\/14651858.CD010294.pub2","volume":"7","author":"D Bolignano","year":"2015","unstructured":"Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GF (2015) Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev 7:Cd010294. doi: 10.1002\/14651858.CD010294.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"9_CR7","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","volume":"10","author":"G Canaud","year":"2010","unstructured":"Canaud G, Knebelmann B, Harris PC, Vrtovsnik F, Correas JM, Pallet N, Heyer CM, Letavernier E, Bienaime F, Thervet E, Martinez F, Terzi F, Legendre C (2010) Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level? Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 10(7):1701\u20131706. doi: 10.1111\/j.1600-6143.2010.03152.x","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"9903","key":"9_CR8","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","volume":"382","author":"A Caroli","year":"2013","unstructured":"Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, Visciano B, Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P, ALADIN study group (2013) Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 382(9903):1485\u20131495. doi: 10.1016\/S0140-6736(13)61407-5","journal-title":"Lancet"},{"issue":"4","key":"9_CR9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bcp.12136","volume":"76","author":"MY Chang","year":"2013","unstructured":"Chang MY, Ong A (2013) New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol 76(4):524\u2013535","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"9_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/ki.2008.596","volume":"75","author":"AB Chapman","year":"2009","unstructured":"Chapman AB (2009) Improving clinical trial design for inquiries into the mechanisms of cyst growth in ADPKD. Kidney Int 75(2):139\u2013141. doi: 10.1038\/ki.2008.596","journal-title":"Kidney Int"},{"issue":"16","key":"9_CR11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJM199010183231602","volume":"323","author":"AB Chapman","year":"1990","unstructured":"Chapman AB, Johnson A, Gabow PA, Schrier RW (1990) The renin\u2013angiotensin\u2013aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 323(16):1091\u20131096","journal-title":"N Engl J Med"},{"issue":"6","key":"9_CR12","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1681\/ASN.V561349","volume":"5","author":"AB Chapman","year":"1994","unstructured":"Chapman AB, Johnson AM, Gabow PA, Schrier RW (1994) Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol JASN 5(6):1349\u20131354","journal-title":"J Am Soc Nephrol JASN"},{"issue":"2","key":"9_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1053\/j.ackd.2010.01.001","volume":"17","author":"AB Chapman","year":"2010","unstructured":"Chapman AB, Stepniakowski K, Rahbari-Oskoui F (2010a) Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 17(2):153\u2013163. doi: 10.1053\/j.ackd.2010.01.001","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"9_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2215\/CJN.04310709","volume":"5","author":"AB Chapman","year":"2010","unstructured":"Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari Oskoui F, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW (2010b) The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol CJASN 5(1):102\u2013109. doi: 10.2215\/CJN.04310709","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"3","key":"9_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ (2012) Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol CJASN 7(3):479\u2013486. doi: 10.2215\/CJN.09500911","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"9_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.59","author":"AB Chapman","year":"2015","unstructured":"Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC, Conference Participants (2015) Autosomal-Dominant Polycystic Kidney Disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. doi: 10.1038\/ki.2015.59","journal-title":"Kidney Int"},{"issue":"6","key":"9_CR17","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2014.01.418","volume":"63","author":"D Chen","year":"2014","unstructured":"Chen D, Ma Y, Wang X, Yu S, Li L, Dai B, Mao Z, Liu H, Liu S, Mei C (2014) Triptolide-containing formulation in patients with autosomal dominant polycystic kidney disease and proteinuria: an uncontrolled trial. Am J Kidney Dis Off J Nat Kidney Found 63(6):1070","journal-title":"Am J Kidney Dis Off J Nat Kidney Found"},{"issue":"1","key":"9_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12881-014-0129-y","volume":"15","author":"R Choi","year":"2014","unstructured":"Choi R, Park HC, Lee K, Lee MG, Kim JW, Ki CS, Hwang YH, Ahn C (2014) Identification of novel PKD1 and PKD2 mutations in Korean patients with autosomal dominant polycystic kidney disease. BMC Med Genet 15(1):129. doi: 10.1186\/s12881-014-0129-y","journal-title":"BMC Med Genet"},{"key":"9_CR19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/1745-6215-12-246","volume":"12","author":"M Chrispijn","year":"2011","unstructured":"Chrispijn M, Drenth JP (2011) Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial. Trials 12:246. doi: 10.1186\/1745-6215-12-246","journal-title":"Trials"},{"issue":"6","key":"9_CR20","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1681\/ASN.2012070650","volume":"24","author":"E Cornec-Le Gall","year":"2013","unstructured":"Cornec-Le Gall E, Audrezet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, Charasse C, Whebe B, Renaudineau E, Jousset P, Guillodo MP, Grall-Jezequel A, Saliou P, Ferec C, Le Meur Y (2013) Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol JASN 24(6):1006\u20131013. doi: 10.1681\/ASN.2012070650","journal-title":"J Am Soc Nephrol JASN"},{"issue":"2","key":"9_CR21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000046231","volume":"21","author":"T Ecder","year":"2001","unstructured":"Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW (2001) Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 21(2):98\u2013103","journal-title":"Am J Nephrol"},{"issue":"2","key":"9_CR22","doi-asserted-by":"crossref","first-page":"C522","DOI":"10.1152\/ajpcell.00163.2010","volume":"301","author":"J Elliott","year":"2011","unstructured":"Elliott J, Zheleznova NN, Wilson PD (2011) c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am J Phys Cell Phys 301(2):C522\u2013C529","journal-title":"Am J Phys Cell Phys"},{"issue":"3","key":"9_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Wiecek A, Zoccali C, Van Biesen W (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Trans Off Publ Eur Dial Trans Assoc Eur Renal Assoc 31(3):337\u2013348. doi: 10.1093\/ndt\/gfv456","journal-title":"Nephrol Dial Trans Off Publ Eur Dial Trans Assoc Eur Renal Assoc"},{"issue":"1","key":"9_CR24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejphar.2010.12.008","volume":"654","author":"J Gao","year":"2011","unstructured":"Gao J, Zhou H, Lei T, Zhou L, Li W, Li X, Yang B (2011) Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. Eur J Pharmacol 654(1):92\u201399","journal-title":"Eur J Pharmacol"},{"key":"9_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2369-13-17","volume":"13","author":"TJ Gevers","year":"2012","unstructured":"Gevers TJ, Chrispijn M, Wetzels JF, Drenth JP (2012) Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. BMC Nephrol 13:17. doi: 10.1186\/1471-2369-13-17","journal-title":"BMC Nephrol"},{"issue":"11","key":"9_CR26","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1681\/ASN.2006080835","volume":"17","author":"PC Harris","year":"2006","unstructured":"Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, Guay-Woodford LM, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Consugar M, Klahr S, Bennett WM, Meyers CM, Zhang QJ, Thompson PA, Zhu F, Miller JP (2006) Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol JASN 17(11):3013\u20133019. doi: 10.1681\/ASN.2006080835","journal-title":"J Am Soc Nephrol JASN"},{"issue":"9147","key":"9_CR27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","volume":"353","author":"N Hateboer","year":"1999","unstructured":"Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning M, Ravine D (1999) Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 study group. Lancet 353(9147):103\u2013107","journal-title":"Lancet"},{"issue":"9","key":"9_CR28","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfu093","volume":"29","author":"E Higashihara","year":"2014","unstructured":"Higashihara E, Nutahara K, Tanbo M, Hara H, Miyazaki I, Kobayashi K, Nitatori T (2014) Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Trans Off Publ Eur Dial Trans Assoc Eur Renal Assoc 29(9):1710\u20131719. doi: 10.1093\/ndt\/gfu093","journal-title":"Nephrol Dial Trans Off Publ Eur Dial Trans Assoc Eur Renal Assoc"},{"issue":"1","key":"9_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1681\/ASN.2013121312","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE (2015) Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol JASN 26(1):39\u201347. doi: 10.1681\/ASN.2013121312","journal-title":"J Am Soc Nephrol JASN"},{"key":"9_CR30","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2015060648","author":"YH Hwang","year":"2015","unstructured":"Hwang YH, Conklin J, Chan W, Roslin NM, Liu J, He N, Wang K, Sundsbak JL, Heyer CM, Haider M, Paterson AD, Harris PC, Pei Y (2015) Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease. J Am Soc Nephrol JASN. doi: 10.1681\/asn.2015060648","journal-title":"J Am Soc Nephrol JASN"},{"issue":"1","key":"9_CR31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1573402111309010008","volume":"9","author":"MV Irazabal","year":"2013","unstructured":"Irazabal MV, Torres VE (2013) Experimental therapies and ongoing clinical trials to slow down progression of ADPKD. Curr Hypertens Rev 9(1):44","journal-title":"Curr Hypertens Rev"},{"issue":"1","key":"9_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE, Investigators C (2015) Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol JASN 26(1):160\u2013172. doi: 10.1681\/ASN.2013101138","journal-title":"J Am Soc Nephrol JASN"},{"issue":"10","key":"9_CR33","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.V8101560","volume":"8","author":"AM Johnson","year":"1997","unstructured":"Johnson AM, Gabow PA (1997) Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol JASN 8(10):1560\u20131567","journal-title":"J Am Soc Nephrol JASN"},{"issue":"1","key":"9_CR34","doi-asserted-by":"publisher","first-page":"e53016","DOI":"10.1371\/journal.pone.0053016","volume":"8","author":"AD Kistler","year":"2013","unstructured":"Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wuthrich RP, Mischak H, Chapman AB (2013) Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One 8(1):e53016. doi: 10.1371\/journal.pone.0053016","journal-title":"PLoS One"},{"issue":"5","key":"9_CR35","doi-asserted-by":"crossref","first-page":"F1193","DOI":"10.1152\/ajprenal.00419.2010","volume":"300","author":"WN Leonhard","year":"2011","unstructured":"Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH, de Heer E, Peters DJ (2011) Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol 300(5):F1193\u2013F1202","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"9_CR36","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/ndt\/gfp777","volume":"25","author":"SJ Leuenroth","year":"2010","unstructured":"Leuenroth SJ, Bencivenga N, Chahboune H, Hyder F, Crews CM (2010) Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD. Nephrol Dial Trans Off Publ Eur Dial Trans Assoc Eur Renal Assoc 25(7):2187\u20132194. doi: 10.1093\/ndt\/gfp777","journal-title":"Nephrol Dial Trans Off Publ Eur Dial Trans Assoc Eur Renal Assoc"},{"issue":"4","key":"9_CR37","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1053\/j.ajkd.2011.12.009","volume":"59","author":"L Li","year":"2012","unstructured":"Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, Toto RD, Wang X, Wright JT Jr, Greene TH (2012) Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis Off J Nat Kidney Found 59(4):504\u2013512. doi: 10.1053\/j.ajkd.2011.12.009","journal-title":"Am J Kidney Dis Off J Nat Kidney Found"},{"issue":"5","key":"9_CR38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2010.06.023","volume":"56","author":"E Meijer","year":"2010","unstructured":"Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, de Jong PE, Gansevoort RT (2010) Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis Off J Nat Kidney Found 56(5):883\u2013895. doi: 10.1053\/j.ajkd.2010.06.023","journal-title":"Am J Kidney Dis Off J Nat Kidney Found"},{"issue":"8","key":"9_CR39","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","volume":"26","author":"E Meijer","year":"2011","unstructured":"Meijer E, Gansevoort RT, de Jong PE, van der Wal AM, Leonhard WN, de Krey SR, van den Born J, Mulder GM, van Goor H, Struck J, de Heer E, Peters DJ (2011) Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Trans Off Publ Eur Dial Trans Assoc Eur Renal Assoc 26(8):2445\u20132453. doi: 10.1093\/ndt\/gfr069","journal-title":"Nephrol Dial Trans Off Publ Eur Dial Trans Assoc Eur Renal Assoc"},{"issue":"3","key":"9_CR40","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1053\/j.ajkd.2013.10.011","volume":"63","author":"E Meijer","year":"2014","unstructured":"Meijer E, Drenth JP, d\u2019Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D, Spithoven EM, Torres VE, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Consortium D (2014) Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis Off J Nat Kidney Found 63(3):446\u2013455. doi: 10.1053\/j.ajkd.2013.10.011","journal-title":"Am J Kidney Dis Off J Nat Kidney Found"},{"key":"9_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-015-1086-2","author":"S Muto","year":"2015","unstructured":"Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T, Ouyang J, Torres VE, Horie S (2015) The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. doi: 10.1007\/s10157-015-1086-2","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"9_CR42","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1681\/asn.2006030251","volume":"17","author":"S Nagao","year":"2006","unstructured":"Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP (2006) Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol JASN 17(8):2220\u20132227. doi: 10.1681\/asn.2006030251","journal-title":"J Am Soc Nephrol JASN"},{"issue":"3","key":"9_CR43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/sj.ki.5002629","volume":"73","author":"S Nagao","year":"2008","unstructured":"Nagao S, Nishii K, Yoshihara D, Kurahashi H, Nagaoka K, Yamashita T, Takahashi H, Yamaguchi T, Calvet JP, Wallace DP (2008) Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy\/+ rat. Kidney Int 73(3):269\u2013277. doi: 10.1038\/sj.ki.5002629","journal-title":"Kidney Int"},{"issue":"7","key":"9_CR44","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/diab.46.7.1182","volume":"46","author":"FS Nielsen","year":"1997","unstructured":"Nielsen FS, Rossing P, Gall M-A, Sk\u00f8tt P, Smidt UM, Parving H-H (1997) Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46(7):1182\u20131188","journal-title":"Diabetes"},{"issue":"5","key":"9_CR45","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1681\/ASN.2011040340","volume":"23","author":"Z Novalic","year":"2012","unstructured":"Novalic Z, van der Wal AM, Leonhard WN, Koehl G, Breuning MH, Geissler EK, de Heer E, Peters DJ (2012) Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol JASN 23(5):842\u2013853. doi: 10.1681\/ASN.2011040340","journal-title":"J Am Soc Nephrol JASN"},{"key":"9_CR46","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12882-015-0075-8","volume":"16","author":"HC Park","year":"2015","unstructured":"Park HC, Kang AY, Jang JY, Kim H, Han M, Oh KH, Kim SH, Noh JW, Cheong HI, Hwang YH, Ahn C (2015) Increased urinary Angiotensinogen\/Creatinine (AGT\/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients. BMC Nephrol 16:86. doi: 10.1186\/s12882-015-0075-8","journal-title":"BMC Nephrol"},{"issue":"1","key":"9_CR47","doi-asserted-by":"publisher","first-page":"c19","DOI":"10.1159\/000320887","volume":"118","author":"Y Pei","year":"2011","unstructured":"Pei Y (2011) Practical genetics for autosomal dominant polycystic kidney disease. Nephron Clin Pract 118(1):c19\u2013c30. doi: 10.1159\/000320887","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"9_CR48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jacc.2011.09.040","volume":"59","author":"J Redon","year":"2012","unstructured":"Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Bohm M, Williams B, Yusoff K, Teo K, Yusuf S (2012) Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 59(1):74\u201383. doi: 10.1016\/j.jacc.2011.09.040","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"9_CR49","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/ki.2013.506","volume":"85","author":"SJ Rosansky","year":"2014","unstructured":"Rosansky SJ, Glassock RJ (2014) Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials? Kidney Int 85(4):723\u2013727. doi: 10.1038\/ki.2013.506","journal-title":"Kidney Int"},{"issue":"1","key":"9_CR50","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","volume":"68","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, Remuzzi G, Epstein FH (2005) Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68(1):206\u2013216. doi: 10.1111\/j.1523-1755.2005.00395.x","journal-title":"Kidney Int"},{"issue":"3","key":"9_CR51","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1681\/asn.2005070697","volume":"17","author":"AD Rule","year":"2006","unstructured":"Rule AD, Torres VE, Chapman AB, Grantham JJ, Guay-Woodford LM, Bae KT, Klahr S, Bennett WM, Meyers CM, Thompson PA, Miller JP (2006) Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol JASN 17(3):854\u2013862. doi: 10.1681\/asn.2005070697","journal-title":"J Am Soc Nephrol JASN"},{"issue":"5","key":"9_CR52","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7326\/0003-4819-142-5-200503010-00009","volume":"142","author":"MJ Sarnak","year":"2005","unstructured":"Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS (2005) The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142(5):342\u2013351","journal-title":"Ann Intern Med"},{"issue":"7","key":"9_CR53","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/01.ASN.0000018407.60002.B9","volume":"13","author":"R Schrier","year":"2002","unstructured":"Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L (2002) Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol JASN 13(7):1733\u20131739","journal-title":"J Am Soc Nephrol JASN"},{"issue":"20","key":"9_CR54","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355(20):2099\u20132112. doi: 10.1056\/NEJMoa065181","journal-title":"N Engl J Med"},{"issue":"24","key":"9_CR55","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB (2014a) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371(24):2255\u20132266. doi: 10.1056\/NEJMoa1402685","journal-title":"N Engl J Med"},{"issue":"11","key":"9_CR56","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1681\/asn.2013111184","volume":"25","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S (2014b) Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol JASN 25(11):2399\u20132418. doi: 10.1681\/asn.2013111184","journal-title":"J Am Soc Nephrol JASN"},{"issue":"9","key":"9_CR57","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wuthrich RP (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363(9):820\u2013829. doi: 10.1056\/NEJMoa0907419","journal-title":"N Engl J Med"},{"issue":"10","key":"9_CR58","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1681\/ASN.2012040367","volume":"23","author":"JM Shillingford","year":"2012","unstructured":"Shillingford JM, Leamon CP, Vlahov IR, Weimbs T (2012) Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol JASN 23(10):1674\u20131681. doi: 10.1681\/ASN.2012040367","journal-title":"J Am Soc Nephrol JASN"},{"issue":"7","key":"9_CR59","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1681\/ASN.2007060665","volume":"19","author":"WE Sweeney","year":"2008","unstructured":"Sweeney WE, von Vigier RO, Frost P, Avner ED (2008) Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 19(7):1331\u20131341","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"9_CR60","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1681\/ASN.2004080660","volume":"16","author":"Y Tao","year":"2005","unstructured":"Tao Y, Kim J, Schrier RW, Edelstein CL (2005) Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol JASN 16(1):46\u201351. doi: 10.1681\/ASN.2004080660","journal-title":"J Am Soc Nephrol JASN"},{"issue":"5","key":"9_CR61","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1523-1755.2005.00703.x","volume":"68","author":"VE Torres","year":"2005","unstructured":"Torres VE (2005) Vasopressin antagonists in polycystic kidney disease. Kidney Int 68(5):2405\u20132418","journal-title":"Kidney Int"},{"issue":"6","key":"9_CR62","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.2215\/CJN.00790209","volume":"4","author":"VE Torres","year":"2009","unstructured":"Torres VE, Bankir L, Grantham JJ (2009) A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol CJASN 4(6):1140\u20131150. doi: 10.2215\/CJN.00790209","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"5","key":"9_CR63","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","volume":"57","author":"VE Torres","year":"2011","unstructured":"Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS (2011) Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3\u20134 study. Am J Kidney Dis Off J Nat Kidney Found 57(5):692\u2013699. doi: 10.1053\/j.ajkd.2010.11.029","journal-title":"Am J Kidney Dis Off J Nat Kidney Found"},{"issue":"25","key":"9_CR64","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, Investigators TT (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367(25):2407\u20132418. doi: 10.1056\/NEJMoa1205511","journal-title":"N Engl J Med"},{"issue":"24","key":"9_CR65","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","volume":"371","author":"VE Torres","year":"2014","unstructured":"Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD, Investigators H-PT (2014) Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med 371(24):2267\u20132276. doi: 10.1056\/NEJMoa1402686","journal-title":"N Engl J Med"},{"key":"9_CR66","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.06300615","author":"VE Torres","year":"2016","unstructured":"Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS (2016) Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol CJASN. doi: 10.2215\/cjn.06300615","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"9_CR67","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1109\/embc.2015.7319043","volume":"2015","author":"D Turco","year":"2015","unstructured":"Turco D, Severi S, Mignani R, Magistroni R, Corsi C (2015) Geometry-independent assessment of renal volume in polycystic kidney disease from magnetic resonance imaging. Conf Proceed Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Conf 2015:3081\u20133084. doi: 10.1109\/embc.2015.7319043","journal-title":"Conf Proceed Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Conf"},{"issue":"5","key":"9_CR68","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","volume":"137","author":"L Keimpema van","year":"2009","unstructured":"van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP (2009) Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 137(5):1661\u20131662. e1661\u2013e1668. doi: 10.1053\/j.gastro.2009.07.052","journal-title":"Gastroenterology"},{"issue":"3","key":"9_CR69","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/ndt\/gfi181","volume":"21","author":"PR Wahl","year":"2006","unstructured":"Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP (2006) Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Trans Off Publ Eur Dial Trans Assoc Eur Renal Assoc 21(3):598\u2013604. doi: 10.1093\/ndt\/gfi181","journal-title":"Nephrol Dial Trans Off Publ Eur Dial Trans Assoc Eur Renal Assoc"},{"issue":"9","key":"9_CR70","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Horl WH, Obermuller N, Arns W, Pavenstadt H, Gaedeke J, Buchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363(9):830\u2013840. doi: 10.1056\/NEJMoa1003491","journal-title":"N Engl J Med"},{"issue":"1","key":"9_CR71","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1681\/ASN.2007060688","volume":"19","author":"X Wang","year":"2008","unstructured":"Wang X, Wu Y, Ward CJ, Harris PC, Torres VE (2008) Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol JASN 19(1):102\u2013108. doi: 10.1681\/ASN.2007060688","journal-title":"J Am Soc Nephrol JASN"},{"issue":"11","key":"9_CR72","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"PB Watkins","year":"2015","unstructured":"Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA (2015) Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf 38(11):1103\u20131113. doi: 10.1007\/s40264-015-0327-3","journal-title":"Drug Saf"},{"issue":"9","key":"9_CR73","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1056\/NEJMe1006925","volume":"363","author":"T Watnick","year":"2010","unstructured":"Watnick T, Germino GG (2010) mTOR inhibitors in polycystic kidney disease. N Engl J Med 363(9):879\u2013881. doi: 10.1056\/NEJMe1006925","journal-title":"N Engl J Med"},{"issue":"15","key":"9_CR74","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358(15):1547\u20131559. doi: 10.1056\/NEJMoa0801317","journal-title":"N Engl J Med"}],"container-title":["Advances in Experimental Medicine and Biology","Cystogenesis"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-10-2041-4_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T21:48:41Z","timestamp":1718833721000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-981-10-2041-4_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9789811020407","9789811020414"],"references-count":74,"URL":"https:\/\/doi.org\/10.1007\/978-981-10-2041-4_9","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2016]]}}}